Closed Studies

Repeat treatment efficacy and safety of Rifaximin in patients with Irritable Bowel Syndrome with Diarrhea (IBS-D)

Approved by the U.S. Food and Drug Administration (FDA) for treating Traveler’s Diarrhea and Hepatic Encephalopathy, this study looks at the efficacy of rifaximin in treating Irritable Bowel Syndrome with Diarrhea (IBS-D). Sponsored by Salix Pharmaceuticals, Inc. the study encompasses approximately 1,850 patients at 250 clinics around the United States.

Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) Study

A Phase 2 Multicentered, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety, Efficacy and Tolerability of Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) in Subjects with Moderately to Severely Active Crohn’s Disease.

Centocor Ulcerative Colitis Study

A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis.

Millennium Ulcerative Colitis Study

A Phase 3, Randomized, Placebo-Controlled Multicenter Study Of The Induction and Maintenance Of Clinical Response And Remission by Vedolizumab In Patients With Moderate To Severe Ulcerative Colitis

Millennium Crohn’s Disease Study

A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab in Patients with Moderate to Severe Crohn’s Disease

Millennium Ulcerative Colitis and Crohn’s Disease Study

A Phase 3, Open-label Study to Determine the Long-Term Safety and Efficacy of Vedolizumab in Patients with Ulcerative Colitis and Crohn’s Disease

HALO Patient Registry: Ablation of Barrett’s Esophagus Design Prospective or Retrospective, Multi-Center Patient Registry

This project was designed to provide a research tool enabling physicians to monitor their clinical outcomes for patients undergoing ablation of Barrett’s esophagus with the HALO Ablation System(s).Outcomes observed: endoscopic clearance rate for Barrett’s esophagus; histological clearance rate for intestinal metaplasia; histological clearance rate for dysplasia; sub-squamous intestinal metaplasia; patient quality of life (baseline vs. 12 month); and adverse event incidence.Enrolled patients to be treated until visibly and histologically clear of Barrett’s esophagus. All patients to have biopsy at 12 months and continue at least yearly surveillance thereafter.

Salix Irritable Bowel Syndrome Study

A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter Study To Assess The Efficacy And Safety Of Rifaximin 550mg TID In The Treatment Of Subjects With Non-Constipation Irritable Bowel Syndrome

Eisai Moderate to Severe Erosive Gastroesophageal Reflux Disease

A Randomized, Double-Blind Parallel Study of Rabeprazole Extended-Release 50mg Versus Esomeprazole 40mg for Healing And Symptomatic Relief Of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)